Aegros' Hyperimmune against Covid-19
Aegros is developing Covimmune™, a hyperimmune against Covid-19, as our first product.
Extensive research and clinical trials are being undertaken because it is vital that this new treatment option against Covid-19 takes its place amongst the medicines that have already been developed. This is because existing treatments have tended to wane in effectiveness over time. Further, there are some patients, particularly those who are immuno-compromised, who cannot benefit from existing therapies.
The video above demonstrates how Aegros' Covimmune™ can keep pace with an elusive virus, maintaining its effectiveness even as the virus changes.